---
title: "Psilocybin (COMP360) in Treatment-resistant depression: Budget impact"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: Budget impact. Topics: Summary: price, reimbursement pathway, and coding; Summary: regulatory and scheduling preconditions for launch; Summary: ICER assessment of synthetic psilocybin; Summary: published cost-effectiveness analyses of psilocybin therapy; 2 further topics. 6 evidence topics quoted from 20 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary/budget-impact"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: Budget impact

<a id="heading-1.1.3"></a>

## 1.1.3 Budget Impact of Psilocybin

<a id="topic-1.1.3-1"></a>

### Summary: price, reimbursement pathway, and coding

No price or wholesale acquisition cost for COMP360 is quoted in any source in this report. On its third quarter 2026 earnings call, the company said pricing depends on “the value that these products are bringing to the healthcare system”, and a news report states that Nath said Spravato “provides a reference point but declined to commit to a specific pricing benchmark.” The company's November 2026 investor presentation states that COMP360 is “expected to be available through specialty pharmacy and buy-and-bill”, with the “drug reimbursed through pharmacy benefit” and session monitoring “billed by the hour through medical benefit” under CPT Category III codes for psychedelic drug monitoring, “effective on January 1, 2024”. The same presentation states that “Coding and reimbursement for COMP360 have not yet been established and are subject to change from current thinking”. On the earnings call, discussing coding and reimbursement, the company said “we anticipate that taking 12-18 months” and that sites would receive coding support and patients would have support programs in the interim. The company's 2026 Form 10-K states that, while psilocybin is in Schedule I, therapies that use it “are currently precluded from reimbursement in the United States.”

Source: [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/); [Keshavan (2026)](https://www.statnews.com/2026/10/14/compass-pathways-psychedelics-stat-summit/); [COMPASS Pathways November investor presentation (2026)](https://s204.q4cdn.com/927483861/files/content_files/DRAFT_CMPS-investor-presentation_NOV026-1.pdf); [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm)

<a id="topic-1.1.3-2"></a>

### Summary: regulatory and scheduling preconditions for launch

The company announced that it “completed its submission of a New Drug Application (NDA)” for COMP360 in treatment-resistant depression. The Commissioner's National Priority Voucher awarded in April 2026 carries a review target of 1 to 2 months after filing. The company anticipates launch “in the first half of 2027 subject to FDA approval and following Drug Enforcement Administration, or DEA, rescheduling.” Its Form 10-K states that psilocybin and psilocin must be rescheduled, or the product scheduled, “to Schedule II, III, IV or V” before commercial marketing, and that “most state laws in the U.S. classify psilocybin and psilocin as Schedule I controlled substances.” On the earnings call the company described the DEA's “90-day statutory timeline” for rescheduling, which it said the White House executive order of 2026 seeks to expedite, and said “over 93% of the U.S. population” lives in states that have stated an intent to reschedule within 30 days after federal action. Prescribing, distribution, and reimbursement of COMP360 therefore follow FDA approval and federal and state rescheduling.

Source: [COMPASS Pathways NDA submission release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Completes-COMP360-Psilocybin-New-Drug-Application-to-U-S--FDA-for-Treatment-Resistant-Depression/default.aspx); [COMPASS Pathways rolling review and voucher release (2026)](https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-FDA-Granted-NDA-Rolling-Review-Request-and-Awarded-Commissioners-National-Priority-Voucher/default.aspx); [COMPASS Pathways Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000076/cmps-20260930.htm); [COMPASS Pathways Form 8-K COMP006 26-week results (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000047/cmps-20260707.htm); [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm); [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/); [White House (2026)](https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/)

<a id="topic-1.1.3-3"></a>

### Summary: ICER assessment of synthetic psilocybin

The Institute for Clinical and Economic Review (ICER) will assess “the comparative clinical effectiveness and value of synthetic psilocybin (COMPASS Pathways) for treatment-resistant depression.” The draft scope names “Psilocybin (25 mg)” as the intervention and esketamine or intravenous ketamine and repetitive transcranial magnetic stimulation as comparators, in adults with major depressive disorder without psychotic features after two or more adequate antidepressant trials in the current episode. The cost-effectiveness model will take a health care system perspective with a five-year base-case horizon, “reflecting uncertainty in the durability of treatment effects”, estimate effectiveness by network meta-analysis, and report cost per QALY, evLY, life-year, and case of remission gained. A separate budget impact analysis over five years will use published or publicly available estimates of the eligible population; the draft scope cites “an estimated 2.8 million” Americans with TRD among those treated for MDD. ICER's schedule lists the revised scoping document on 11/18/2026, the model analysis plan on 01/22/2027, the draft evidence report on 03/16/2027, and the final evidence report and meeting summary on 06/21/2027.

Source: [ICER (2026)](https://icer.org/news-insights/press-releases/institute-for-clinical-and-economic-review-to-assess-therapy-for-treatment-resistant-depression/); [ICER TRD assessment page (2026)](https://icer.org/assessment/treatment-resistant-depression-2027/); [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_TRD_Draft-Scope_For-Publication_102126-1.pdf)

<a id="topic-1.1.3-4"></a>

### Summary: published cost-effectiveness analyses of psilocybin therapy

Three peer-reviewed analyses model psilocybin therapy in depression; none states a price for COMP360.

- 12 months, limited healthcare perspective: with an assumed total therapy cost of $5000 (varied from $3000 to $20,000), psilocybin-assisted therapy added 0.031 QALYs and $3639 in costs compared with standard of care, an incremental ratio of $117,517 per QALY gained, with a 75% probability of cost-effectiveness at $150,000 per QALY. That probability was 1% at a total cost of $10,000 and 95% at $3000.
- PubMed abstract: compared with standard of care, therapy was “more effective and less costly”, with approximately $7000 in savings and 0.10 QALYs gained per patient; a 30-year horizon gave savings of $215 900 and 9.87 QALYs.
- Costs in pounds sterling: expected healthcare cost of therapy was £6132 to £7652 depending on the psilocybin price, with 0.310 QALYs for psilocybin against 0.278 to 0.287 for the alternatives. Psilocybin was cost-effective when therapist support cost fell by 50% and the drug price fell to £400 to £800 per person.

Source: [Avanceña et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12397412/); [Ziadi and Park (2026)](https://pubmed.ncbi.nlm.nih.gov/41842876/); [McCrone et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10755218/)

<a id="topic-1.1.3-5"></a>

### Summary: comparator costs and utilization

- Esketamine, ICER 2019: at a WAC of “$295 per 28 mg device”, an annual average WAC of $32,400, ICER estimated approximately $198,000 per QALY gained and $2.6 million per life-year gained. Annual prices of $17,700 and $25,200 would meet thresholds of $100,000 and $150,000 per QALY, a discount from WAC of “25-52%”.
- Esketamine, published analysis: base-case ratios were $237,111 per QALY (societal) and $242,496 per QALY (healthcare sector), and the value-based price at $150,000 per QALY was approximately $140 per dose against a current price of $240 per dose.
- Cohorts initiating esketamine (151), electroconvulsive therapy (198), or transcranial magnetic stimulation (140): mean mental health-related inpatient costs were $76, $1,547, and $238, and outpatient costs were $1,632, $1,023, and $1,051; the authors state the comparison “should be interpreted with caution”.
- Utilization: the company states that fewer than 3% of an estimated 4 million people in the United States with TRD are treated with Spravato.

Source: [ICER final evidence report (2019)](https://icer.org/wp-content/uploads/2020/10/ICER_TRD_Final_Evidence_Report_062019.pdf); [Ross and Soeteman (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7920520/); [Clemens et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/43010363/); [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/)

<a id="topic-1.1.3-6"></a>

### Summary: delivery-model cost drivers

- Session length: a COMP360 administration session “lasts approximately six to eight hours”, which the company contrasts with the “six hours versus two hours requirement” for Spravato.
- Monitoring staff: the company's trial design used “one primary monitor” with closed-circuit television, “two total healthcare providers” in all, and it anticipates REMS requirements “no more stringent” than in the trials. Group monitoring saved 34.7% of clinician costs, or $981 per patient, for psilocybin in major depressive disorder in one published analysis.
- REMS: the company expects a REMS, states that the FDA directed it to use the Spravato REMS as a template, and states in its Form 10-K that REMS programs “are costly and time-consuming for providers to comply with”. REMS training content is expected to take “about one to two hours to review.”
- Treatment-center capacity: the company cites “more than 8,500 interventional psychiatry treatment centers” in the United States.
- Payer views: a payer panel raised concern about the cost-effectiveness of “potentially requiring multiple health professionals at specialized centers”.

Source: [COMPASS Pathways Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000020/cmps-20251231.htm); [COMPASS Pathways third quarter earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/11/03/compass-pathways-cmps-q3-2026-earnings-call-transcript/); [Marseille et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10731307/); [Flavin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13520776/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
